Sign In
Buy CABA
$3.58
-0.100 (-2.72%)
At Close: Jun 03, 2026
The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance
02:26pm, Thursday, 30'th Jan 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 29) 10X Genomics Inc (NASDAQ: TXG ) Agile Therapeutics
FDA Grants DSG3-CAART Orphan Drug Designation for the Treatment of Pemphigus Vulgaris
01:00pm, Wednesday, 29'th Jan 2020
Cabaletta Bio, Inc. (CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today
3 Stocks with Growth Prospects in the Triple Digits
09:32am, Monday, 23'rd Dec 2019
The objective of any investor is a simple one: to make money.While this objective couldn’t be clearer, it is much harder putting it into action. How is one to spot the potential of a stock on a down
Cabaletta Bio to Present at the Evercore ISI 2nd Annual HealthCONx Conference
01:00pm, Tuesday, 26'th Nov 2019
PHILADELPHIA, Nov. 26, 2019 -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell.
The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study
11:32am, Tuesday, 29'th Oct 2019
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 28.) AstraZeneca plc (NYSE: AZN ) ( reported p
Cabaletta Bio Announces Pricing of Initial Public Offering
11:36am, Friday, 25'th Oct 2019
PHILADELPHIA, Oct. 25, 2019 -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical stage biotechnology company focused on the discovery and development of engineered T cell.
Avalon Globocare (AVCO) Stock: The Wolf of Wall Street?
05:54pm, Friday, 25'th Jan 2019
Low-priced biotech stocks are often targets of pump-and-dump manipulation scams or other activity designed to make money for a select few, not you (think
Cabaletta Bio Closes $50M Series B Financing | FinSMEs
05:54pm, Wednesday, 09'th Jan 2019
Cabaletta Bio, a biotech company focused on the development of T cell therapies for B cell-mediated autoimmune diseases, closed a $50m Series B financing
An Introduction to Cancer Immunotherapy Treatments
09:35pm, Wednesday, 27'th Dec 2017
Of all the things that your doctor could tell you that might be a cause for alarm, hearing that you have late-stage cancer is probably one of the worst. We've all heard people talk about a 'cure for c
